On June 4, 2024, the plenary session of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) was held in Fukuoka, Japan, at which the National Medical Products Administration (NMPA) was elected as a member of the ICH Management Committee for the third time. ICH is an international organization that formulates and coordinates the technical standards for the R&D and registration of new drugs in different countries. The NMPA joined the ICH in 2017 and was elected as a member of the ICH Management Committee twice in 2018 and 2021. Being re-elected as a member of the ICH Management Committee for the third time this year indicates that China is in line with the international rules in new drug R&D and registration technical standards, and that the internationalization process of drug administration has been recognized internationally. It also signifies a significant enhancement of China's voice in international organizations.

Going forward, the NMPA will adhere to the development directions of being scientific, legalized, internationalized, and modernized. It will actively participate in the international coordination of ICH topics, continue to promote the alignment of domestic drug review standards to international ones, and make every effort to boost the new drug R&D in China, driving China's transformation from a big pharmaceutical manufacturing country to a powerful one.